Pipeline
We are committed to identifying unmet needs and harnessing the full potential of science to treat challenging human diseases. Our discoveries have led to the development of new treatments that have improved patients’ lives worldwide.
Shionogi has a long history of small molecule drug discovery. Our current pipeline includes projects across several therapeutic areas, including infectious disease. We are advancing clinical programs for infectious disease, rare disease, acute ischemic stroke and oncology.
Learn more about the investigational compounds currently in our U.S. pipeline below.
Featured Programs
Ensitrelvir Fumaric Acid
COVID-19 continues to impact daily life. Following exposure to COVID-19, the best way to avoid its potentially serious and long-term complications is to stop viral replication, which prevents the development of the disease. Ensitrelvir is an investigational oral antiviral, being evaluated for the prevention of COVID-19 following exposure to an infected individual. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting the main protease.
Cefiderocol
Shionogi is evaluating cefiderocol in pediatric patients, birth to 17 years of age. Multidrug-resistant and carbapenem-resistant Gram-negative infections affect children globally.
Zatolmilast in Fragile X Syndrome
Fragile X syndrome (FXS) is a genetic condition that is the most common cause of inherited cognitive disability. FXS can cause challenges across many aspects of daily life, such as impacting individuals’ ability to care for themselves and communicate with others. Zatolmilast is an investigational drug that is believed to work by increasing a signaling compound called cAMP, which when increased may promote the maturation of connections between neurons that are impaired in patients with FXS.
Zatolmilast in Jordan's Syndrome
Jordan’s Syndrome is a rare genetic neurodevelopmental disorder characterized by global developmental delays, seizures, physical characteristics, vision problems, muscle weakness, attention disorder, social and sensory challenges commonly associated with autism, disordered sleep and feeding difficulties. Zatolmilast is an investigational drug that is believed to work by increasing a signaling compound called cAMP, which when increased may promote the maturation of connections between neurons.
U.S. Pipeline
These compounds and their uses are investigational and have not all been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview and should not be construed as a recommendation for use of any product for unapproved uses.